U.S. Physical Therapy, Inc. (USPH) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$73.61
Price Target
$102.00
Target Range
$102.00 — $102.00
Analyst Rating
Buy
Forward P/E25.7x
Trailing P/E51.8x
Forward PEG—
Implied Growth+23.5%
Median Target$102.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$102
+38.6%
Consensus
$102
+38.6%
Bull Case
$102
+38.6%
Valuation Model TargetsConfidence: 53/100
Bear$78
Base$125
Bull$175
USPH Price Target Analysis
Updated May 7, 2026As of May 7, 2026, U.S. Physical Therapy, Inc. (USPH) has a Wall Street consensus price target of $102.00, based on estimates from 12 covering analysts. With the stock currently trading at $73.61, this represents a potential upside of +38.6%. The company has a market capitalization of $1.12B.
Analyst price targets range from a low of $102.00 to a high of $102.00, representing a 0% spread in expectations. The median target of $102.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, USPH trades at a trailing P/E of 51.8x and forward P/E of 25.7x. Analysts expect EPS to grow +23.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $125.38, with bear and bull scenarios of $78.06 and $174.67 respectively. Model confidence stands at 53/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+20.8%
Avg Forward P/E32.9x
Peers with Coverage8 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 AFCGAdvanced Flower Capital Inc. | $65M | $2.77 | — | — | — | — | — |
 CCRNCross Country Healthcare, Inc. | $326M | $10.11 | $10.61 | +4.9% | Hold | 103.4x | 14 |
 NHCNational HealthCare Corporation | $2.6B | $169.41 | — | — | — | 21.3x | — |
 ENSGThe Ensign Group, Inc. | $10.3B | $175.93 | $222.33 | +26.4% | Buy | 23.4x | 13 |
 ACHCAcadia Healthcare Company, Inc. | $2.3B | $25.30 | $23.50 | -7.1% | Buy | 17.0x | 25 |
 SEMSelect Medical Holdings Corporation | $2.0B | $16.43 | $18.00 | +9.6% | Hold | 13.1x | 13 |
 SGRYSurgery Partners, Inc. | $1.9B | $14.59 | $18.60 | +27.5% | Buy | 38.7x | 22 |
 OPCHOption Care Health, Inc. | $3.2B | $20.45 | $33.00 | +61.4% | Buy | 11.0x | 14 |
 ADUSAddus HomeCare Corporation | $1.8B | $96.64 | $128.67 | +33.1% | Buy | 14.0x | 15 |
 HIMSHims & Hers Health, Inc. | $6.9B | $26.88 | $29.67 | +10.4% | Hold | 53.9x | 19 |
Upside Potential Comparison
OPCHADUSSGRYENSGHIMSSEMCCRNACHCSee USPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs USPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare USPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonUSPH — Frequently Asked Questions
Quick answers to the most common questions about buying USPH stock.
What is the USPH stock price target for 2026?
The consensus Wall Street price target for USPH is $102, representing 38.6% upside from the current price of $73.61. With 12 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is USPH a buy, sell, or hold?
USPH has a consensus rating of "Buy" based on 12 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $102 implies 38.6% upside from current levels.
Is USPH stock overvalued or undervalued?
USPH trades at a forward P/E of 25.7378x, representing a moderate valuation. With analysts targeting $102 (38.6% implied move), the stock appears reasonably valued with upside.
How high can USPH stock go?
The most bullish Wall Street analyst has a price target of $102 for USPH, while the most conservative target is $102. The consensus of $102 represents the median expectation. Our quantitative valuation model projects a bull case target of $175 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover USPH stock?
USPH is moderately covered, with 12 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the USPH stock forecast?
The 12-month USPH stock forecast based on 12 Wall Street analysts shows a consensus price target of $102, with estimates ranging from $102 (bear case) to $102 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $125, with bear/bull scenarios of $78/$175.
What is USPH's fair value based on fundamentals?
Our quantitative valuation model calculates USPH's fair value at $125 (base case), with a bear case of $78 and bull case of $175. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 53/100.
What is USPH's forward P/E ratio?
USPH trades at a forward P/E ratio of 25.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 51.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy USPH stock?
Wall Street analysts are very optimistic on USPH, with a "Buy" consensus rating and $102 price target (38.6% upside). 9 of 12 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do USPH price targets vary so much?
USPH analyst price targets range from $102 to $102, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $102 consensus represents the middle ground. Our model's $78-$175 range provides an independent fundamental perspective.